BD Tops Q3 Forecasts and Lifts Full-Year EPS Guidance Midpoint
BDX sits 35% above its 52-week low of $127.536.
Summary
BD posted Q3 fiscal 2026 revenue of $5.0 billion, up 5.4%, with adjusted EPS of $3.23 beating expectations. The company raised the midpoint of its full-year adjusted EPS guidance and highlighted strong cash flow growth.
Key Events · Earnings and Guidance · BDX
-
Q3 Revenue and EPS Beat
Revenue of $5.0 billion grew 5.4% reported, or 4.4% on a currency-neutral basis. Adjusted diluted EPS of $3.23 exceeded expectations, driven by strength across all four segments.
-
Full-Year Guidance Raised
BD raised the midpoint of its adjusted diluted EPS guidance to $12.62–$12.72 from $12.52–$12.72, and now expects revenue growth toward the high end of its low single-digit plus range.
-
Cash Flow Surge
Year-to-date cash from continuing operations increased 33.3% to $2.1 billion, and free cash flow jumped 44.6% to $1.7 billion, reflecting improved working capital and profitability.
-
First Full Quarter as Pure-Play MedTech
These results represent the first full quarter following the February 2026 spin-off of the Biosciences and Diagnostic Solutions business, showcasing the focused 'New BD' strategy.
Analysis · BDX · Industrial Applications And Services
A strong third quarter saw BD surpass expectations on revenue, adjusted operating margin, and adjusted EPS. Reflecting sustained momentum across all four segments, the company raised the midpoint of its full-year adjusted diluted EPS guidance to $12.62–$12.72. Cash generation improved markedly, with year-to-date free cash flow climbing 44.6% to $1.7 billion, which provides ample capacity for strategic capital deployment. These results mark the first full quarter as a pure-play MedTech company following the spin-off of the Biosciences and Diagnostic Solutions business.
At the time of this filing, BDX was trading at $172.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $47B. The 52-week trading range was $127.54 to $187.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.